We develop a platform technology for generating domain- and epitope-specific molecular probes that precisely visualize the binding sites of cancer drugs within tumor tissue. Our goal is to create a tumor-agnostic diagnostic approach that can ultimately be made available to all cancer patients, providing accurate, tissue-based insights for therapy selection. In addition, we use our platform to offer drug developers unique insights into the binding behavior of new compounds across different tumor entities—enabling more targeted and lower-risk drug development. We also develop molecular probes and antibodies for research use only (RUO) to support and advance academic research in this field.